rs1555760738
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 6P and 4B. PVS1_StrongPP5_ModerateBS2
The NM_004343.4(CALR):c.1099_1150delCTTAAGGAGGAGGAAGAAGACAAGAAACGCAAAGAGGAGGAGGAGGCAGAGG(p.Leu367fs) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000301 in 1,460,220 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★).
Frequency
Genomes: 𝑓 0.000020 ( 0 hom., cov: 31)
Exomes 𝑓: 0.000030 ( 0 hom. )
Failed GnomAD Quality Control
Consequence
CALR
NM_004343.4 frameshift
NM_004343.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 8.15
Genes affected
CALR (HGNC:1455): (calreticulin) Calreticulin is a highly conserved chaperone protein which resides primarily in the endoplasmic reticulum, and is involved in a variety of cellular processes, among them, cell adhesion. Additionally, it functions in protein folding quality control and calcium homeostasis. Calreticulin is also found in the nucleus, suggesting that it may have a role in transcription regulation. Systemic lupus erythematosus is associated with increased autoantibody titers against calreticulin. Recurrent mutations in calreticulin have been linked to various neoplasms, including the myeloproliferative type.[provided by RefSeq, May 2020]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 2 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.124 CDS is truncated, and there are 0 pathogenic variants in the truncated region.
PP5
Variant 19-12943750-AGCAGAGGCTTAAGGAGGAGGAAGAAGACAAGAAACGCAAAGAGGAGGAGGAG-A is Pathogenic according to our data. Variant chr19-12943750-AGCAGAGGCTTAAGGAGGAGGAAGAAGACAAGAAACGCAAAGAGGAGGAGGAG-A is described in ClinVar as [Pathogenic]. Clinvar id is 97006.Status of the report is criteria_provided_single_submitter, 1 stars.
BS2
High AC in GnomAdExome4 at 44 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CALR | NM_004343.4 | c.1099_1150delCTTAAGGAGGAGGAAGAAGACAAGAAACGCAAAGAGGAGGAGGAGGCAGAGG | p.Leu367fs | frameshift_variant | 9/9 | ENST00000316448.10 | NP_004334.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CALR | ENST00000316448.10 | c.1099_1150delCTTAAGGAGGAGGAAGAAGACAAGAAACGCAAAGAGGAGGAGGAGGCAGAGG | p.Leu367fs | frameshift_variant | 9/9 | 1 | NM_004343.4 | ENSP00000320866.4 |
Frequencies
GnomAD3 genomes AF: 0.00 AC: 3AN: 152176Hom.: 0 Cov.: 31 FAILED QC
GnomAD3 genomes
AF:
AC:
3
AN:
152176
Hom.:
Cov.:
31
FAILED QC
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.0000301 AC: 44AN: 1460220Hom.: 0 AF XY: 0.0000441 AC XY: 32AN XY: 726272
GnomAD4 exome
AF:
AC:
44
AN:
1460220
Hom.:
AF XY:
AC XY:
32
AN XY:
726272
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Data not reliable, filtered out with message: AS_VQSR AF: 0.0000197 AC: 3AN: 152176Hom.: 0 Cov.: 31 AF XY: 0.0000269 AC XY: 2AN XY: 74348
GnomAD4 genome
Data not reliable, filtered out with message: AS_VQSR
AF:
AC:
3
AN:
152176
Hom.:
Cov.:
31
AF XY:
AC XY:
2
AN XY:
74348
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:3Other:4
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
Essential thrombocythemia Other:2
-, no assertion criteria provided | clinical testing | Molecular Diagnostics Laboratory, Fox Chase Cancer Center - Temple Health | Jan 24, 2024 | A large majority of myeloproliferative neoplasms with nonmutated JAK2 exhibit somatic CALR mutations. In a subset of such cases with essential thrombocythemia, 67% had CALR mutation. - |
-, no assertion criteria provided | clinical testing | Molecular Diagnostics Laboratory, Fox Chase Cancer Center - Temple Health | Jan 24, 2024 | In a cohort of 1107 myeloproliferative neoplasm patients, those with "mutated CALR had a lower risk of thromobsis and longer overall survival than patients with mutated JAK2." - |
Acute myeloid leukemia Other:2
-, no assertion criteria provided | clinical testing | Molecular Diagnostics Laboratory, Fox Chase Cancer Center - Temple Health | Jan 24, 2024 | While there are strong associations of this variant to thrombocythemia and myeloproliferative neoplasms, its oncogenicity and clinical impact in this case of acute myeloid leukemia is uncertain because the allele frequency decreased over time from 11% (progressive thrombocythemia) to 3% (AML in remission) to undetectable at AML relapse. - |
-, no assertion criteria provided | clinical testing | Molecular Diagnostics Laboratory, Fox Chase Cancer Center - Temple Health | Jan 24, 2024 | While there are strong associations of this variant to thrombocythemia and myeloproliferative neoplasms, its oncogenicity and clinical impact in this case of acute myeloid leukemia is uncertain because the allele frequency decreased over time from 11% (progressive thrombocythemia) to 3% (AML in remission) to undetectable at AML relapse. - |
Thrombocythemia 1 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 19, 2013 | - - |
Primary myelofibrosis Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 19, 2013 | - - |
Primary myelofibrosis;C3277671:Thrombocythemia 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Feb 10, 2022 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at